NCCN Clinical Practice Guidelines in Oncology Prostate Cancer
NCCN Clinical Practice Guidelines in Oncology Prostate Cancer
Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, available on Medscape, was developed by a panel of 25 multidisciplinary non-small cell lung cancer experts from NCCN Member Institutions. The panel met in July 2009 to review evidence and formulate updated recommendations. All NCCN Guidelines are updated at least once a year with additional updates published when important new data that change practice standards are released. The update process includes extensive review of the current NCCN Guidelines via institutional reviews at NCCN Member Institutions and review of recently published data, and formal input from the patient advocacy community. An agenda for the panel meeting is developed and panel members are assigned to present data regarding each agenda item. Relevant publications and results of the institutional review are distributed to NCCN Panel Members before the meeting.
The published NCCN Guidelines has 3 parts: an algorithm that follows the step-by-step clinical decision-making process; a discussion which reviews the data the recommendations are based on and the issues that were considered by the panel; and a bibliography. Each recommendation is categorized according to both the level of evidence supporting the recommendation and the degree of consensus among the NCCN Member Institutions that the recommendation is appropriate.
All NCCN Panel Members volunteer their time and expertise and accept no compensation for their efforts. They declare any potential conflicts of interest both in writing and verbally to each other. NCCN Panel Members may be excluded from discussion of related topics if it is perceived that they have a significant conflict, at the discretion of the chair. Data may be submitted to the panel by the community, patient advocacy organizations, or industry representatives. Industry representatives are not allowed to participate in the panel discussions, nor are they allowed to make presentations to the NCCN Guidelines Panel. The NCCN Guidelines Panel has sole responsibility for evaluating data and determining the content of the NCCN Guidelines.
NCCN Guidelines development is completely supported by NCCN Member Institution dues to NCCN. NCCN may accept industry funding only for dissemination of the NCCN Guidelines.
The NCCN Guidelines for Prostate Cancer is one of the Complete Library of NCCN Clinical Practice Guidelines in Oncology™, which is available free of charge at NCCN.org. The most recent version of each NCCN Guidelines is always available on NCCN's website.
Click here to view: NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, Version 1.2010
Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, available on Medscape, was developed by a panel of 25 multidisciplinary non-small cell lung cancer experts from NCCN Member Institutions. The panel met in July 2009 to review evidence and formulate updated recommendations. All NCCN Guidelines are updated at least once a year with additional updates published when important new data that change practice standards are released. The update process includes extensive review of the current NCCN Guidelines via institutional reviews at NCCN Member Institutions and review of recently published data, and formal input from the patient advocacy community. An agenda for the panel meeting is developed and panel members are assigned to present data regarding each agenda item. Relevant publications and results of the institutional review are distributed to NCCN Panel Members before the meeting.
The published NCCN Guidelines has 3 parts: an algorithm that follows the step-by-step clinical decision-making process; a discussion which reviews the data the recommendations are based on and the issues that were considered by the panel; and a bibliography. Each recommendation is categorized according to both the level of evidence supporting the recommendation and the degree of consensus among the NCCN Member Institutions that the recommendation is appropriate.
All NCCN Panel Members volunteer their time and expertise and accept no compensation for their efforts. They declare any potential conflicts of interest both in writing and verbally to each other. NCCN Panel Members may be excluded from discussion of related topics if it is perceived that they have a significant conflict, at the discretion of the chair. Data may be submitted to the panel by the community, patient advocacy organizations, or industry representatives. Industry representatives are not allowed to participate in the panel discussions, nor are they allowed to make presentations to the NCCN Guidelines Panel. The NCCN Guidelines Panel has sole responsibility for evaluating data and determining the content of the NCCN Guidelines.
NCCN Guidelines development is completely supported by NCCN Member Institution dues to NCCN. NCCN may accept industry funding only for dissemination of the NCCN Guidelines.
The NCCN Guidelines for Prostate Cancer is one of the Complete Library of NCCN Clinical Practice Guidelines in Oncology™, which is available free of charge at NCCN.org. The most recent version of each NCCN Guidelines is always available on NCCN's website.
Click here to view: NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, Version 1.2010
Source...